From NAFLD to NASH to cirrhosis—new insights into disease mechanisms

@article{Wree2013FromNT,
  title={From NAFLD to NASH to cirrhosis—new insights into disease mechanisms},
  author={Alexander Wree and Lori Broderick and Ali Canbay and Hal M Hoffman and Ariel E. Feldstein},
  journal={Nature Reviews Gastroenterology \&Hepatology},
  year={2013},
  volume={10},
  pages={627-636}
}
NAFLD has evolved as a serious public health problem in the USA and around the world. In fact, NASH—the most serious form of NAFLD—is predicted to become the leading cause of liver transplantation in the USA by the year 2020. The pathogenesis of NAFLD and NASH, in particular the mechanisms responsible for liver injury and fibrosis, is the result of a complex interplay between host and environmental factors, and is at the centre of intense investigation. In this Review, we focus on recently… Expand
Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
TLDR
The current epidemiology, diagnosis, animal models, pathogenesis, and treatment strategies for NAFLD are comprehensively reviewed, emphasizing the outstanding breakthroughs in the above fields and promising medications in and beyond phase II. Expand
The genetics of NAFLD
TLDR
The current status of the field is described, discussing specific genetic and epigenetic modifiers, including the mechanisms through which genes identified by genome-wide association studies, including PNPLA3, influence disease progression. Expand
Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
TLDR
Current findings and knowledge regarding the pathogenesis of NASH are reviewed, focusing on the most recent advances and hormone-based therapeutic approaches for treatment ofNASH are highlighted. Expand
Evolving therapies for non-alcoholic steatohepatitis
TLDR
Treatment of NAFLD is still in its infancy, although large controlled studies have demonstrated some efficacy for pioglitazone or vitamin E, and the authors highlight the current most promising treatment strategies in NASH/NAFLD. Expand
Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
TLDR
The NLRP3 inflammasome is an intracellular multiprotein complex involved in the production of mature interleukin 1-beta and induces metabolic inflammation that has been recently demonstrated to play a crucial role in the progression of NASH. Expand
A Review of Pharmacological Treatments of NASH
TLDR
A clinical review of the pharmacological treatment of NASH in the last years due to the increasing incidence of NAFLD and NASH around the world and the long term safety of several agents remain to be established. Expand
NASH and the Cross-Talk Between the Gut and Liver
TLDR
An overview of the current knowledge on the pathophysiology of the cross-talk between the gut and the liver in the pathogenesis of NAFLD and its progression to NASH is provided, and potential therapeutic means to manipulate the intestinal microbiota in order to modulate liver disease development are discussed. Expand
Steatosis and Steatohepatitis: Complex Disorders
TLDR
An overview about the currently available knowledge and recent findings regarding the development and progression of non-alcoholic fatty liver disease is given. Expand
Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack
TLDR
The current understanding of the cellular and molecular processes that govern macrophage contribution to NAFLD pathogenesis and how adipose tissue and liver crosstalk modulates macrophages function are reviewed to lead to the development of new therapies forNAFLD. Expand
Importance of iron overload and steatosis in patients with chronic liver disease
TLDR
An increased number of regulatory T-cells and CD68 cells in NASH, pointing at an involvement of both the adaptive and innate immune systems, and the association between hepcidin and iron parameters, lipid status and inflammatory markers in NAFLD in relation to other chronic liver diseases. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 121 REFERENCES
The epidemiology of nonalcoholic fatty liver disease: a global perspective.
TLDR
The burden of NAFLD is expected to increase in years to come as a result of an aging population and the improving control of other major causes of chronic liver disease, such as hepatitis C and hepatitis B. Expand
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
TLDR
Endoplasmic reticulum stress and related signaling networks, (adipo)cytokines, and innate immunity are emerging as central pathways that regulate key features of NASH. Expand
Good fat/bad fat
TLDR
A more complex model of steatosis was used, employing db/db mice fed a methionine-restricted, choline-deficient (MCD) diet, and there was some optimism that blocking DGAT2, which catalyzes the final step in hepatic triglyceride production, may be beneficial in NAFLD/NASH. Expand
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
TLDR
Altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders. Expand
Management of nonalcoholic steatohepatitis: an evidence-based approach.
TLDR
This review of NASH management addresses current data from the perspective of levels of evidence for therapeutic options in NASH, including lifestyle modification, drug therapies, and bariatric surgery. Expand
Obesity Affects the Liver – The Link between Adipocytes and Hepatocytes
TLDR
This review summarizes current knowledge – highlighting the inflammatory and cytokine view – of the intimate relationship between adipose and liver tissue and suggests reduced adiponectin levels may establish a proinflammatory milieu, thus increasing vulnerability to lipotoxicity. Expand
Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
TLDR
NAFLD/NASH as the hepatic entity of the MS may itself pose a risk factor for HCC, even in the absence of cirrhosis, and increased awareness of liver manifestations in theMS may instigate early interventions against developing HCC. Expand
The interaction of hepatic lipid and glucose metabolism in liver diseases.
TLDR
Novel findings related to nuclear receptor signaling in hepatic lipid and glucose uptake, storage and metabolism in the clinical context of non-alcoholic fatty liver disease, liver regeneration, and cancer are focused on. Expand
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.
TLDR
Hepatocyte apoptosis is significantly increased in patients with NASH and correlates with disease severity, suggesting that antiapoptotic therapy may be useful in this syndrome. Expand
Mechanisms of hepatic fibrogenesis.
TLDR
Clinical and translational implications of these advances have become clear, and have begun to impact significantly on the management and outlook of patients with chronic liver disease. Expand
...
1
2
3
4
5
...